MACROMOLECULAR COMPLEX OF BACTERIAL ORIGIN AND USE OF SAID MACROMOLECULAR COMPLEX FOR PREVENTING AND TREATING INFLAMMATORY RHEUMATISM

• US 20130130988A1
• Filed: 07/05/2011
• Published: 05/23/2013
• Est. Priority Date: 07/05/2010
• Status: Active Grant

• Current Assignee: Bifinove Co.
• Original Assignee: Bifinove Co.
• Inventors: Blareau, Jean-Pierre, Romond, Charles, Colavizza, Michel, Huguet, Frederic
• Granted Patent: US 9,416,160 B2
• Time in Patent Office: Days
• US Class Current: 514/16.6
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23L 33/195 Proteins from microorganisms
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/3204 Probiotics, living bacteria to be ingested for action in the digestive tract
• CPC Class Codes: A23V 2200/324 having an effect on the immune system
• CPC Class Codes: A23V 2250/28 Oligosaccharides
• CPC Class Codes: A23V 2250/546 Microbial protein
• CPC Class Codes: A61K 38/164 from bacteria
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 14/00 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• CPC Class Codes: C07K 14/195 from bacteria
• CPC Class Codes: C12N 1/00 Microorganisms, e.g. protozoa; Compositions thereof medicinal preparations containing material from protozoa, bacteria or viruses A61K35/66, from algae A61K36/02, from fungi A61K36/06; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, A61K39/00; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
• CPC Class Codes: C12N 1/20 Bacteria; Culture media therefor
• CPC Class Codes: C12P 1/04 by using bacteria
• CPC Class Codes: C12P 19/04 Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds

Abstract

A bacterial macromolecular complex produced by bacteria belonging to the Bifidobacterium longum strain deposited according to the treaty of Budapest under number CNCM I-3994 with the Collection Nationale de Cultures de Microorganismes (CNCM) [National Collection of Microorganism Cultures], consisting of chains combining a lipoprotein and an oligosaccharide, wherein:

the lipoprotein has a molecular weight of from 30 kDa to 60 kDa;

the oligosaccharide has a molecular weight of less than 15 kDa, and preferably less than 10 kDa;

the lipoprotein component, which consists of all the lipoproteins of each of the chains, represents from 75 to 99%, preferentially from 80 to 98%, more preferentially from 85 to 95% by weight of the total weight of the complex, and the oligosaccharide component, which consists of all the oligosaccharides combined with each of the chains, represents from 1 to 25%.

Claims

1. A bacterial macromolecular complex which can be produced by bacteria belonging to the Bifidobacterium longum strain deposited according to the treaty of Budapest under number CNCM I-3994, on May 23, 2008, with the Collection Nationale de Cultures de Microorganismes (CNCM) [National Collection of Microorganism Cultures], consisting of chains combining a lipoprotein and an oligosaccharide, characaterized in that:

the lipoprotein has a molecular weight of from 30 kDa to 60 kDa;

the oligosaccharide has a molecular weight of less than 15 kDa, and preferably less than 10 kDa;

the lipoprotein component, which consists of all the lipoproteins of each of the chains, represents from 75 to 99%, preferentially from 80 to 98%, more preferentially from 85 to 95% by weight of the total weight of the complex, and the oligosaccharide component, which consists of all the oligosaccharides combined with each of the chains, represents from 1 to 25%, preferentially from 2 to 20%, and more preferentially from 5 to 15% of the total weight of the complex.

2. The macromolecular complex as claimed in claim 1, having a molecular weight of greater than 150 kDa.

3. The macromolecular complex as claimed in claim 1, wherein the lipoprotein comprises the amino acid sequence SEQ ID 1.

4. The macromolecular complex as claimed in claim 1, wherein the amino acid sequence of the lipoprotein is SEQ ID 2.

5. The macromolecular complex as claimed in claim 1, wherein the saccharides constituting the saccharide component of the macromolecular complex are chosen from galactose (Gal), N-acetylgalactosamine (Gal Nac), glucose (Glc), N-acetylglucosamine (Glc Nac), rhamnose (Rham), and mannose (Man), and mixtures thereof.

6. The macromolecular complex as claimed in claim 5, wherein the average weight composition of galactose is between 1 and 50 μ

g/mg of macromolecular complex, preferably between 5 and 20 μ

g/mg of macromolecular complex, and of mannose is between 0.5 and 10 μ

g/mg of macromolecular complex, preferably between 1 and 10 μ

g/mg of macromolecular complex;

that of glucose is between 3 and 80 μ

g/mg of macromolecular complex, preferably between 5 and 50 μ

g/mg of macromolecular complex, and even more preferably between 10 and 50 μ

g/mg of macromolecular complex;

that of N-acetylgalactosamine is between 2 and 30 μ

g/mg of macromolecular complex, preferably between 2 and 20 μ

g/mg of macromolecular complex, and even more preferentially between 2 and 10 μ

g/mg of macromolecular complex;

that of N-acetylglucosamine is between 1 and 10 μ

g/mg of macromolecular complex, preferably between 1 and 5 μ

g/mg of macromolecular complex;

that of rhamnose is between 0.05 and 10 μ

g/mg of macromolecular complex, preferably between 0.05 and 5 μ

g/mg of macromolecular complex, and even more preferentially between 1 and 5 μ

g/mg of macromolecular complex.

7. The macromolecular complex as claimed in claim 1, wherein lipids constituting the lipid component of the macromolecular complex are chosen from the group consisting of long C14, C16 and C18 saturated fatty acids, and mixtures thereof.

8. A pharmaceutical composition, wherein it comprises at least the macromolecular complex as claimed in claim 1, as active ingredient, and at least one pharmaceutically acceptable support.

9. A pharmaceutical composition comprising at least the macromolecular complex as claimed in claim 1, as active ingredient, and at least one pharmaceutically acceptable support, and wherein claim 8 the weight concentration of the macromolecular complex represents from 0.1 to 50 μ

g/g of the pharmaceutical composition.

10. The pharmaceutical composition as claimed in claim 8, for use in regulating the intestinal flora and bacterial translocation.

11. The pharmaceutical composition as claimed in claim 8, for use in the treatment or prevention of inflammatory rheumatism, osteoarthritis and fibromyalgia.

12. A food composition comprising at least said macromolecular complex as claimed in claim 1, and at least one food ingredient.

13. A food composition comprising at least said macromolecular complex as claimed in claim 1, and at least one food ingredient, wherein the weight concentration of the macromolecular complex represents from 10 ng/g to 2 μ

g/g of the food composition.

14. The food composition as claimed in claim 12, wherein the food composition is in the form of food products.

15. A nutraceutical composition comprising at least said macromolecular complex as claimed in claim 1, and at least one nutraceutically acceptable support.

16. A nutraceutical composition comprising at least said macromolecular complex as claimed in claim 1, and at least one nutraceutically acceptable support, wherein the weight concentration of the macromolecular complex represents from 10 ng/g to 5 μ

g/g of the nutraceutical composition.

17. The nutraceutical composition as claimed in claim 15, wherein the nutraceutical composition is in the form of food supplements.

18. The nutraceutical composition as claimed in claim 15, for use in the prevention of inflammatory rheumatism, osteoarthritis and fibromyalgia.

20. The macromolecular complex as claimed in claim 2, wherein the lipoprotein comprises the amino acid sequence SEQ ID 1.

19. The strain of Bifidobacterium longum bacteria, deposited according to the treaty of Budapest under number CNCM I-3994, on May 23, 2008, with the Collection Nationale de Cultures de Microorganismes (CNCM) [National Collection of Microorganism Cultures].